Then, we speculate that in the future, attention to ApoA1 polymorphism, alongside the known allele variant Apo E ε4, might increase the predictivity for AD onset and the cluster of pathologies, such as AD metabolic syndrome or AD dyslipidemia. This evidence concerns the gene APOE and Alzheimer disease.